Barr Pharmaceuticals BRL
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… on capital over the long haul. Paul Bisaro has been president and CEO of Watson since 2007. Bisaro came from Barr Pharmaceuticals , where he worked since 1992, most recently as president and COO. Some of the directors, including Andrew …
-
Teva Acquires Ratiopharm
… 186 million (a total value of approximately $4.95 billion). Teva’s last major acquisition was that of Barr Pharmaceuticals , a US-based multinational generic pharmaceutical company with operations mainly in the US and Europe. This …
-
New Morningstar Analyst Report - Celgene
… lead to pricing pressure down the road.Teva-owned Barr Pharmaceuticals has filed for approval of a generic version of Thalomid ..... competitive pressures are also mounting. Teva TEVA-owned Barr Pharmaceuticals is attempting to launch a generic version of Thalomid …
-
Sector Focus: Health Care
… act of consolidation was last year’s acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries , the world ..... Asia its greatest prospective growth markets and bought Barr Pharmaceuticals partly because of Barr’s substantial presence …
-
Teva May Postpone Barr Acquisition
We're maintaining our fair value estimate for Barr Pharmaceuticals BRL at Teva's TEVA negotiated acquisition price of $67 per share despite a breakdown in the commercial paper market that could make …
-
Par under Review
… in these areas take the steam out of any near-term growth. It's also a sign of the company's inability to compete effectively against the larger, more efficient, U.S. generic competitors like Mylan MYL, Barr BRL , and Teva TEVA.
-
Strong 2Q for Mylan
… generic oral contraceptives in 2010; this pact would shake up the longstanding generic oral contraceptives duopoly between Barr BRL and Watson WPI. The pending acquisition of Barr by Teva TEVA announced last quarter consolidates two major global competitors …
-
Teva Agrees to Buy Barr
Teva Pharmaceutical TEVA agreed Friday to buy Barr Pharmaceuticals BRL for $67 per share. We're bringing Barr's fair value estimate in line with the purchase price, as we believe the deal will …
-
Rumored Barr-Teva Combo Makes Sense
Barr Pharmaceuticals ' BRL stock price rose 20% today on rumors of a potential buyout from Teva TEVA. While unconfirmed by either party, the proposed price …
-
Barr under Review
We're placing Barr Pharmaceuticals ' BRL fair value estimate under review following Thursday's disappointing first-quarter results. We expect to decrease our fair …